Current status of composite tissue allotransplantation.
Composite tissue allotransplantation (CTA) is emerging as a potential treatment for complex tissue defects. A major drawback for CTA remains the requirement of lifelong immunosuppression. Up to date numerous experimental CTA models have been introduced to the transplantation literature. After the first hand transplantation in 1998, the clinical applicability of CTA has attracted a lot of attention. This article will outline the historical background of CTA and our experience in different CTA models.
Siemionow
M
M
Plastic Surgery/Microsurgery, Cleveland Clinic, Cleveland, Ohio 44195, USA. siemiom@hotmail.com
Bozkurt
M
M
Kulahci
Y
Y
D000818:Animals; D016025:Bone Transplantation / Q000379:methods*; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects; D006614:Hindlimb / Q000637:transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007830:Larynx / Q000098:blood supply / Q000637:transplantation; D008437:Maxilla / Q000637:transplantation; D008866:Microsurgery; D051381:Rats; D011919:Rats, Inbred Strains; D013524:Surgical Flaps / Q000098:blood supply*; D016378:Tissue Transplantation / Q000379:methods*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents